Data Rooms for Life Sciences and Clinical Trials

Life-sciences VDR use cases: biotech licensing, asset divestitures, clinical-trial diligence, contract research transfers: sit at the intersection of M&A workflows and a uniquely demanding regulatory environment. Documents include preclinical and clinical study data, IND / CTA filings, manufacturing records, IP registrations, and GxP-controlled SOPs.

European life-sciences practice is concentrated in Basel (Roche, Novartis), Cambridge UK and Cambridge MA-adjacent (biotech), Munich and Berlin (German biotech), Copenhagen (Novo-adjacent), Paris (Sanofi-adjacent), Leiden / Amsterdam (Dutch biotech), and Stockholm (Karolinska-adjacent). VDRs serving these projects must support GxP-compliant audit trails, 21 CFR Part 11-style electronic-records integrity, and GDPR-compliant clinical-trial data handling.

This page covers how to configure a life-sciences VDR for European deals, the regulatory frameworks that shape configuration choices, and which providers are typically shortlisted.

Published: May 2026. Updated: 18 June 2026.

Document Categories

  • Preclinical: toxicology, pharmacology, ADME, formulation development.
  • Clinical: IND / CTA filings, study reports, patient narratives, statistical analyses.
  • Manufacturing: CMC, batch records, BMF / DMF, supplier qualifications.
  • Regulatory: submissions to EMA, FDA, MHRA, Swissmedic; correspondence; meeting minutes.
  • IP: patent prosecution files, freedom-to-operate analyses, licensing history.
  • GxP: SOPs, deviations, CAPAs, audit records.
  • Commercial: supply agreements, distribution, market access, pricing.

Regulatory and Data-Protection Considerations

  • GDPR + clinical-trial data. Clinical-trial subject data is special-category personal data; VDR access must be tightly controlled, with subject-name pseudonymization typical.
  • EU Clinical Trial Regulation 536/2014. Clinical Trial Information System (CTIS) is the EU portal; VDR documents must align with CTIS submissions.
  • 21 CFR Part 11-style audit trails. US-touching projects expect electronic records integrity; ISO 27001 + audit trail features satisfy this in practice.
  • GxP (GMP/GLP/GCP). Standard operating procedures and deviations require version-controlled storage and indelible audit trails.
  • HDS (France). French health data must sit on certified Hébergeur de Données de Santé infrastructure; typically scoped out of the general VDR.

Providers Used for European Life-Sciences Deals

  • [Drooms](/providers/drooms): large pharma carve-outs and asset divestitures.
  • [Papermark](/providers/papermark): biotech licensing and growth-stage funding rounds.
  • [idgard](/providers/idgard): for German pharma where §203 StGB / professional secrecy is in play.
  • [Admincontrol](/providers/admincontrol): Nordic biotech, particularly Copenhagen.
  • Datasite / Intralinks: large pharma carve-outs.

Frequently Asked Questions

Is clinical-trial data special-category data under GDPR?

Yes: health data is one of the special categories of personal data under Article 9 GDPR. Processing requires an explicit legal basis and additional safeguards. In practice, VDRs use pseudonymization of subject identifiers and tight access controls.

Can a general-purpose VDR satisfy GxP requirements?

Most can in practice, provided they offer indelible audit trails, version control, and ISO 27001 certification. Some pharma buyers require a specific GxP qualification statement from the provider.

What about French HDS requirements?

French health data must sit on certified HDS infrastructure. Most general-purpose VDRs are not natively HDS-certified, so French health data is typically scoped out of the VDR or stored in a specialist HDS-certified store linked to the VDR through a controlled handover.

Are biotech licensing VDRs different from M&A VDRs?

Slightly: they tend to be more scientific-document-heavy (full study reports, statistical analyses, preclinical raw data) and have a longer pre-deal phase as the licensee performs scientific diligence.

Further Reading